You are here: Industry Insights > Olumiant

News List

Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation worldpharmanews
August 04, 2021
Eli Lilly and Company and Incyte announced results from an additional cohort of 101 adult patients from the COV-BARRIER trial. In this sub-study, patients with COVID-19 on mechanical ventilation or extracorporeal membrane oxygenation (ECMO) who ...
EMA to assess if Olumiant should be authorised for hospitalised COVID-19 patients europeanpharmaceuticalreview
May 06, 2021
The EMA will conduct an accelerated assessment and issue its decision on whether Olumiant (baricitinib) can be used in hospitalised COVID-19 patients by July.
New Progress in the Hair Loss Prevention Drug Market: JAK Inhibitor Baricitinib Reaches Phase 3 Clinical Primary Endpoint PharmaSources.com
March 26, 2021
Eli Lilly and Company and Incyte jointly announced on Mar. 3, 2021 that baricitinib, an oral JAK inhibitor, met its primary endpoint in Phase 3 clinical trial for the treatment of adult patients with severe alopecia areata (AA).
Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients prnewswire
June 16, 2020
Eli Lilly and Company announced that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed from Incyte, ...
Eli Lilly’s COVID-19 therapies to enter clinical trials europeanpharmaceuticalreview
April 17, 2020
The enterprise announced its drug OLUMIANT® (baricitinib) and an investigational antibody will enter clinical trials in US COVID-19 patients later this month.
Lilly to test Olumiant, LY3127804 against COVID-19 pharmatimes
April 14, 2020
Lilly has linked with health officials in the US to assess its rheumatoid arthritis drug Olumiant (baricitinib) in patients hospitalised with COVID-19.
FDA Approves Olumiant drugs
June 12, 2018
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved the 2-mg dose of Olumiant (baricitinib),
US approves Lilly/Incyte’s Olumiant pharmatimes
June 06, 2018
As expected, US regulators have approved the lower dose of Eli Lilly/Incyte’s once-daily JAK inhibitor Olumiant as treatment for rheumatoid arthritis (RA).
Eli Lilly and Incyte receive EC’s marketing authorisation approval for Olumiant pharmaceutical-technology
February 16, 2017
Eli Lilly and Incyte have secured marketing authorisation approval for Olumiant (baricitinib) 4mg and 2mg film-coated tablets from the European Commission (EC) to treat moderate-to-severe active rheumatoid arthritis (RA) in adult patients.